BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Torres C, Grippo PJ. Pancreatic cancer subtypes: a roadmap for precision medicine. Ann Med 2018;50:277-87. [PMID: 29537309 DOI: 10.1080/07853890.2018.1453168] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Hii LW, Lim SE, Leong CO, Chin SY, Tan NP, Lai KS, Mai CW. The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma. BMC Complement Altern Med 2019;19:257. [PMID: 31521140 DOI: 10.1186/s12906-019-2663-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
2 Gardi N, Ketkar M, McKinnon RA, Pandol SJ, Dutt S, Barreto SG. Down-regulation of metabolic pathways could offset the poor prognosis conferred by co-existent diabetes mellitus in pancreatic (head) adenocarcinoma. ANZ J Surg 2021. [PMID: 34514690 DOI: 10.1111/ans.17194] [Reference Citation Analysis]
3 Casati G, Giunti L, Iorio AL, Marturano A, Galli L, Sardi I. Hippo Pathway in Regulating Drug Resistance of Glioblastoma. IJMS 2021;22:13431. [DOI: 10.3390/ijms222413431] [Reference Citation Analysis]
4 Kim H, Jang KT. Pathologic interpretation of endoscopic ultrasound-guided fine needle aspiration cytology/biopsy for pancreatic lesions. J Pathol Transl Med 2020;54:367-77. [PMID: 32854488 DOI: 10.4132/jptm.2020.07.21] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Li S, Mai Z, Gu W, Ogbuehi AC, Acharya A, Pelekos G, Ning W, Liu X, Deng Y, Li H, Lethaus B, Savkovic V, Zimmerer R, Ziebolz D, Schmalz G, Wang H, Xiao H, Zhao J. Molecular Subtypes of Oral Squamous Cell Carcinoma Based on Immunosuppression Genes Using a Deep Learning Approach. Front Cell Dev Biol 2021;9:687245. [PMID: 34422810 DOI: 10.3389/fcell.2021.687245] [Reference Citation Analysis]
6 Benzel J, Fendrich V. Familial Pancreatic Cancer. Oncol Res Treat. 2018;41:611-618. [PMID: 30269130 DOI: 10.1159/000493473] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
7 Yeo D, Giardina C, Saxena P, Rasko JEJ. The next wave of cellular immunotherapies in pancreatic cancer. Mol Ther Oncolytics 2022;24:561-76. [PMID: 35229033 DOI: 10.1016/j.omto.2022.01.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 Monberg ME, Geiger H, Lee JJ, Sharma R, Semaan A, Bernard V, Wong J, Wang F, Liang S, Swartzlander DB, Stephens BM, Katz MHG, Chen K, Robine N, Guerrero PA, Maitra A. Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution. Nat Commun 2022;13:3652. [PMID: 35752636 DOI: 10.1038/s41467-022-31376-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tan DJ, Mitra M, Chiu AM, Coller HA. Intron retention is a robust marker of intertumoral heterogeneity in pancreatic ductal adenocarcinoma. NPJ Genom Med 2020;5:55. [PMID: 33311498 DOI: 10.1038/s41525-020-00159-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
10 Yamakawa K, Nakano-Narusawa Y, Hashimoto N, Yokohira M, Matsuda Y. Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment. Int J Mol Sci 2019;20:E4224. [PMID: 31470511 DOI: 10.3390/ijms20174224] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
11 Zhan T, Zhu Q, Han Z, Tan J, Liu M, Liu W, Chen W, Chen X, Chen X, Deng J, Tian X, Huang X. miR-455-3p Functions as a Tumor Suppressor by Restraining Wnt/β-Catenin Signaling via TAZ in Pancreatic Cancer. Cancer Manag Res 2020;12:1483-92. [PMID: 32161500 DOI: 10.2147/CMAR.S235794] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Schizas D, Koumpoura A, Galari M, Economopoulou P, Vailas M, Sotiropoulou M, Dimitroulis D, Maroulis I, Felekouras E. A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice. Per Med 2021;18:613-27. [PMID: 34676789 DOI: 10.2217/pme-2021-0031] [Reference Citation Analysis]
13 Fei X, Kong L, Shi C, Wang G, Liu C, Wang C, Liu P, Tan X, Bu D. Identification of Prognosis-Related Molecular Subgroups and Construction of a Prognostic Prediction Model Using Immune-Related Genes in Pancreatic Cancer. Journal of Oncology 2022;2022:1-21. [DOI: 10.1155/2022/7117014] [Reference Citation Analysis]
14 Mäkinen L, Vähä-koskela M, Juusola M, Mustonen H, Wennerberg K, Hagström J, Puolakkainen P, Seppänen H. Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring. Cancers 2022;14:525. [DOI: 10.3390/cancers14030525] [Reference Citation Analysis]
15 Zhou C, Li H, Han X, Pang H, Wu M, Tang Y, Luo X. Prognostic Value and Molecular Mechanisms of Proteasome 26S Subunit, Non-ATPase Family Genes for Pancreatic Ductal Adenocarcinoma Patients after Pancreaticoduodenectomy. J Invest Surg 2021;:1-17. [PMID: 33525943 DOI: 10.1080/08941939.2020.1863527] [Reference Citation Analysis]
16 Sun J, Ambrus JI, Baker JR, Russell CC, Cossar PJ, Sakoff JA, Scarlett CJ, McCluskey A. 3,5-Bis(trifluoromethyl)phenylsulfonamides, a novel pancreatic cancer active lead. Investigation of the terminal aromatic moiety. Bioorg Med Chem Lett 2022;:128591. [PMID: 35114371 DOI: 10.1016/j.bmcl.2022.128591] [Reference Citation Analysis]
17 Aquilani R, Brugnatelli S, Maestri R, Boschi F, Filippi B, Perrone L, Barbieri A, Buonocore D, Dossena M, Verri M. Peripheral Blood Lymphocyte Percentage May Predict Chemotolerance and Survival in Patients with Advanced Pancreatic Cancer. Association between Adaptive Immunity and Nutritional State. Curr Oncol 2021;28:3280-96. [PMID: 34449579 DOI: 10.3390/curroncol28050285] [Reference Citation Analysis]
18 Rehman H, Chi J, Hakim N, Goyal SP, Olazagasti C, Jose J, Moriarty L, Saif MW. Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer. Therap Adv Gastroenterol 2020;13:1756284820974912. [PMID: 33281939 DOI: 10.1177/1756284820974912] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Zheng-Lin B, O'Reilly EM. Pancreatic ductal adenocarcinoma in the era of precision medicine. Semin Oncol 2021:S0093-7754(21)00005-1. [PMID: 33637355 DOI: 10.1053/j.seminoncol.2021.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Elsayed M, Abdelrahim M. The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. Biomedicines 2021;9:389. [PMID: 33917380 DOI: 10.3390/biomedicines9040389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Pietri E, Balsano R, Coriano M, Gelsomino F, Leonardi F, Bui S, Gnetti L, Valle RD, Garajová I. The implication of liquid biopsies to predict chemoresistance in pancreatic cancer. Cancer Drug Resist 2021;4:559-72. [PMID: 35582309 DOI: 10.20517/cdr.2021.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 [DOI: 10.1101/2021.01.13.426413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Li C, Chen X, Ren X, Chen JL, Chen H, Yu JJ, Ran QC, Kang S, Chen XM, Zhao ZJ. Identification of Hypoxia-Related Molecular Classification and Associated Gene Signature in Oral Squamous Cell Carcinoma. Front Oncol 2021;11:709865. [PMID: 34888229 DOI: 10.3389/fonc.2021.709865] [Reference Citation Analysis]
24 Davis JM, Cheng B, Drake MM, Yu Q, Yang B, Li J, Liu C, Younes M, Zhao X, Bailey JM, Shen Q, Ko TC, Cao Y. Pancreatic stromal Gremlin 1 expression during pancreatic tumorigenesis. Genes Dis 2022;9:108-15. [PMID: 35005111 DOI: 10.1016/j.gendis.2020.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Liu X, Chen B, Chen J, Sun S. A novel tp53-associated nomogram to predict the overall survival in patients with pancreatic cancer. BMC Cancer 2021;21:335. [PMID: 33789615 DOI: 10.1186/s12885-021-08066-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Raja Arul GL, Toruner MD, Gatenby RA, Carr RM. Ecoevolutionary biology of pancreatic ductal adenocarcinoma. Pancreatology 2022:S1424-3903(22)00197-1. [PMID: 35821188 DOI: 10.1016/j.pan.2022.06.005] [Reference Citation Analysis]
27 Ungefroren H, Christl J, Eiden C, Wellner UF, Lehnert H, Marquardt JU. Autocrine TGFβ1 Opposes Exogenous TGFβ1-Induced Cell Migration and Growth Arrest through Sustainment of a Feed-Forward Loop Involving MEK-ERK Signaling. Cancers (Basel) 2021;13:1357. [PMID: 33802809 DOI: 10.3390/cancers13061357] [Reference Citation Analysis]
28 Chen H, Zhu X, Sun R, Ma P, Zhang E, Wang Z, Fan Y, Zhou G, Mao R. Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance. Invest New Drugs 2020;38:1707-16. [PMID: 32468271 DOI: 10.1007/s10637-020-00951-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Creeden JF, Alganem K, Imami AS, Brunicardi FC, Liu SH, Shukla R, Tomar T, Naji F, McCullumsmith RE. Kinome Array Profiling of Patient-Derived Pancreatic Ductal Adenocarcinoma Identifies Differentially Active Protein Tyrosine Kinases. Int J Mol Sci 2020;21:E8679. [PMID: 33213062 DOI: 10.3390/ijms21228679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
30 Doffo J, Bamopoulos SA, Köse H, Orben F, Zang C, Pons M, den Dekker AT, Brouwer RWW, Baluapuri A, Habringer S, Reichert M, Illendula A, Krämer OH, Schick M, Wolf E, van IJcken WFJ, Esposito I, Keller U, Schneider G, Wirth M. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Proc Natl Acad Sci U S A 2022;119:e2105691119. [PMID: 35197278 DOI: 10.1073/pnas.2105691119] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Yu Y, Wang Z, Mo DH, Wang Z, Li G. Transcriptome profiling reveals liver metastasis-associated genes in pancreatic ductal adenocarcinoma. Math Biosci Eng 2021;18:1708-21. [PMID: 33757206 DOI: 10.3934/mbe.2021088] [Reference Citation Analysis]
32 Zhang Y, Ma Y, Wang Y, Mukhopadhyay D, Bi Y, Ji B. Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth. Pancreatology 2022. [DOI: 10.1016/j.pan.2022.03.019] [Reference Citation Analysis]
33 Orhan A, Vogelsang RP, Andersen MB, Madsen MT, Hölmich ER, Raskov H, Gögenur I. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis. Eur J Cancer 2020;132:71-84. [PMID: 32334338 DOI: 10.1016/j.ejca.2020.03.013] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
34 Tarasiuk A, Mackiewicz T, Małecka-Panas E, Fichna J. Biomarkers for early detection of pancreatic cancer - miRNAs as a potential diagnostic and therapeutic tool? Cancer Biol Ther 2021;22:347-56. [PMID: 34224317 DOI: 10.1080/15384047.2021.1941584] [Reference Citation Analysis]
35 He M, Wang X, Xu J, Li J, Chang X, Zins M, Jin Z, Xue H. Diffuse Involvement of Pancreas is not Always Autoimmune Pancreatitis. Acad Radiol 2022:S1076-6332(22)00063-0. [PMID: 35279380 DOI: 10.1016/j.acra.2022.01.013] [Reference Citation Analysis]
36 Mancinelli G, Torres C, Krett N, Bauer J, Castellanos K, McKinney R, Dawson D, Guzman G, Hwang R, Grimaldo S, Grippo P, Jung B. Role of stromal activin A in human pancreatic cancer and metastasis in mice. Sci Rep 2021;11:7986. [PMID: 33846512 DOI: 10.1038/s41598-021-87213-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]